Entity

Time filter

Source Type

Harrow on the Hill, United Kingdom

Crook S.H.,University of Sheffield | Mann B.E.,University of Sheffield | Meijer A.J.H.M.,University of Sheffield | Adams H.,University of Sheffield | And 3 more authors.
Dalton Transactions | Year: 2011

[Mn(CO)4{S2CNMe(CH2CO2H)}], 1, is shown to be a CO releasing molecule providing at least three moles CO per mole of compound. The mechanism of CO loss is dissociative and reversible and was investigated using Gaussian 09 calculations. The reversible binding of CO results in a relatively stable solution of the compound, while in the presence of a CO receptor or a ligand to prevent the rebinding of CO, the CO is lost rapidly. The X-ray structure was determined. © 2011 The Royal Society of Chemistry. Source


Patent
Northwick Park Institute For Medical Research | Date: 2010-02-05

Methods for the detection or diagnosis of a bacterial infection or colonisation utilising mass spectrometric analysis are provided. The methods involve short-term enrichment of samples followed by mass spectrometric analysis of biomarker profiles. Also provided are methods for preparing short-term enrichment cultures.


De Castro Bras L.E.,Northwick Park Institute for Medical Research | Proffitt J.L.,Covidien | Bloor S.,Covidien | Sibbons P.D.,Northwick Park Institute for Medical Research
Journal of Biomedical Materials Research - Part B Applied Biomaterials | Year: 2010

One of the main problems in healthcare is the loss of tissues resulting from diseases, post-surgery complications or trauma. As a result there is a need for biomaterials designed to promote tissue regeneration and improve wound healing. This study assessed the effect of crosslinking of a porcine dermal collagen matrix with regard to strength of implant/host tissue integration, implant biocompatibility and general healing in a rodent model. Permacol™, a crosslinked acellular collagenous biomaterial was compared with its noncrosslinked equivalent at 3, 6, and 12 months postsubcutaneous implantation. Both matrices were well tolerated and showed no evidence of inflammation or adverse responses either in the host tissue or implants. Progressive integration of the implants with the surrounding tissue was observed. Cellular response was similar for both collagenous matrices although, at 3 and 6 months, noncrosslinked implants showed a significantly higher level of cellular penetration than crosslinked implants. However, at 12 months crosslinked implants showed significantly higher levels of cellular density, neo-vascularisation and integration with host tissue. Additionally, at long term, noncrosslinked implants lost volume suggesting some absorption. The crosslinking process does not seem to be detrimental to cellular response and biocompatibility. © 2010 Wiley Periodicals, Inc. Source


Prabhu I.S.,University of Manchester | Homer-Vanniasinkam S.,Northwick Park Institute for Medical Research
Journal of Cranio-Maxillofacial Surgery | Year: 2013

The aim of this proof-of-principle study was to assess an intraluminal expandable stent design using an existing cardiac stent. Intraluminal stents minimise the amount of suturing necessary when performing an end-to-end anastomosis. The stent is passed halfway through the lumen on each end of the vessel to be anastomosed and is expanded using a retrievable balloon. An adequately expanded stent holds the blood vessel ends in contact without the need for sutures. This method was tested on an end-to-end anastomosis performed on the carotid vessels of two New Zealand male rabbits. The vessels were patent with good blood flow at the end of 16 days. This method has a potential use in vascular, microvascular and luminal anastomoses within various sub-specialities of surgery. © 2012 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved. Source


Hoerauf A.,University of Bonn | Townson S.,Northwick Park Institute for Medical Research | Slatko B.E.,New England Biolabs
Parasitology | Year: 2014

SUMMARY Anti-Wolbachia therapy delivers safe macrofilaricidal activity with superior therapeutic outcomes compared to all standard anti-filarial treatments, with the added benefit of substantial improvements in clinical pathology. These outcomes can be achieved, in principle, with existing registered drugs, e.g. doxycycline, that are affordable, available to endemic communities and have well known, albeit population-limiting, safety profiles. The key barriers to using doxycycline as an mass drug administration (MDA) strategy for widespread community-based control are the logistics of a relatively lengthy course of treatment (4-6 weeks) and contraindications in children under eight years and pregnancy. Therefore, the primary goal of the anti-Wolbachia (A·WOL) consortium is to find drugs and regimens that reduce the period of treatment from weeks to days (7 days or less), and to find drugs which would be safe in excluded target populations (pregnancy and children). A secondary goal is to refine regimens of existing antibiotics suitable for a more restricted use, prior to the availability of a regimen that is compatible with MDA usage. For example, for use in the event of the emergence of drug-resistance, in individuals with high loiasis co-infection and at risk of severe adverse events (SAE) to ivermectin, or in post-MDA 'endgame scenarios', where test and treat strategies become more cost effective and deliverable. © Cambridge University Press 2013. Source

Discover hidden collaborations